Cathie Wood Trims Pfizer Stake And Loads Up $25M In Rival COVID-19 Vaccine Maker

Cathie Wood led Ark Invest on Wednesday initiated a position in Moderna Inc MRNA after the biotech company said an updated version of its COVID-19 booster vaccine appeared to provide stronger protection against the Omicron variant than its current shot. 

St. Petersburg, Florida-based Ark Invest bought 172,939 shares, estimated to be worth $25.68 million, in Moderna.

Moderna closed 2.2% higher at $148.5 on Wednesday. The stock, which is down 36.8% so far this year, has risen 9% in the past month.

Ark Invest bought the Moderna shares via its flagship pharma-linked exchange fund Ark Genomic Revolution ETF ARKG on Wednesday. 

See Also: Moderna's Updated COVID-19 Shot Boosts Omicron Protection

The money managing firm, however, sold 152,823 shares — estimated to be worth $8.17 million — in rival Pfizer Inc PFE on Wednesday. 

Shares of the biotech firm, which is boosting production of its oral COVID-19 pill, closed 0.9% lower at $53.4. The stock is down 5.6% year-to-date. Pfizer has been seeking FDA approval for three COVID-19 vaccine doses for children under five.

Ark Invest held 732, 993 shares, worth $39.5 million, in Pfizer before Wednesday’s trade. The investment firm has been selling shares in Pfizer for months now.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechLong IdeasNewsSector ETFsBroad U.S. Equity ETFsShort IdeasTrading IdeasETFsGeneralARK Investment ManagementCathie WoodCOVID-19 Vaccine
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!